Research news

Research update January 2024 – NET update copy

COVID Guidelines​ – Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era

Clinical Trials​ –  Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177 Lu-Dotatate: an analysis of the NETTER-1 study​3

Basic Science​ –  Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy

Reviews and Clinical Papers

Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences

Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas.

Surgery management for sporadic small (≤2 cm), non-functioning pancreatic neuroendocrine tumors

Baseline plasma chromogranin A levels in patients with well-differentiated neuroendocrine tumors of the pancreas

Frequent Presence of Lymphovascular Invasion in Small Rectal Neuroendocrine Tumors on Immunohistochemical Analysis.

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumours

Additional malignancies in patients with neuroendocrine tumours: analysis of the SwissNET registry

Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastroenteropancreatic Neuroendocrine Tumors and Unknown Primary Sites

Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours.

The Ki-67 labelling index and lymphatic/venous permeation predict the metastatic potential of rectal neuroendocrine tumors